Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222288 | 1.00 | HCRTR2 (0.40) | HCRTR2SMN1; SMN2EPHX1HSD17B10CHRM2 | |
| SCHEMBL24918246 | 1.00 | HCRTR2 (0.40) | HCRTR2SMN1; SMN2EPHX1HSD17B10CHRM2 | |
| SCHEMBL31239802 | 0.86 | SMN1; SMN2 (0.38) | HCRTR2SMN1; SMN2EPHX1HSD17B10CHRM2 | |
| SCHEMBL31239832 | 0.84 | SMN1; SMN2 (0.37) | HCRTR2SMN1; SMN2EPHX1HSD17B10CHRM2 | |
| SCHEMBL26656268 | 0.81 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL24918211 | 0.78 | HPGD (0.41) | SMN1; SMN2EPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL24917703 | 0.78 | HPGD (0.41) | SMN1; SMN2EPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL31239951 | 0.78 | HPGD (0.41) | SMN1; SMN2EPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL24917728 | 0.78 | HPGD (0.41) | SMN1; SMN2EPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL31239988 | 0.78 | HPGD (0.41) | SMN1; SMN2EPHX1HSD17B10CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| WO-2024229447-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-117916238-A | Compositions and methods for inhibiting RAS | 瑟拉斯有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | HCRTR2 4695/4885SMN1; SMN2 2634/4885EPHX1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.